1-Benzofuran-6-Carboxylic Acid for Sterile Ophthalmic API Synthesis

Trace Metal-Catalyzed Degradation Pathways in Ophthalmic Formulations Using 1-Benzofuran-6-carboxylic Acid

When formulating sterile ophthalmic solutions, the presence of trace metals in 1-Benzofuran-6-carboxylic acid (CAS 77095-51-3) can initiate degradation pathways that compromise both stability and patient safety. Our field experience with this heterocyclic building block reveals that copper and iron residues, even at sub-ppm levels, catalyze Fenton-type reactions in aqueous-organic hybrid systems commonly used for eye drops. These reactions generate hydroxyl radicals that attack the benzofuran ring, leading to discoloration and the formation of genotoxic impurities. In one case, a batch stored at 25°C/60% RH developed a yellow tint within three months, traced back to 0.8 ppm iron carryover from a previous synthesis campaign. This non-standard parameter—color shift under accelerated conditions—is rarely documented but critical for ophthalmic applications. To mitigate this, we recommend chelating agents like EDTA in the formulation buffer, but the primary defense is sourcing 6-Benzofurancarboxylic Acid with certified low metal content. Our high-purity 1-Benzofuran-6-carboxylic acid is manufactured under controlled conditions to minimize these risks, ensuring your API synthesis starts with a clean slate.

ICP-MS Testing Protocols and Actionable Limits for Copper and Iron in Sterile API Intermediates

For ophthalmic-grade 6-carboxy-benzofuran, we enforce strict inductively coupled plasma mass spectrometry (ICP-MS) protocols. Based on ICH Q3D guidelines for parenteral products, our actionable limits are ≤1.0 ppm for copper and ≤2.0 ppm for iron, but we routinely achieve <0.5 ppm for both. A typical COA will list these values; please refer to the batch-specific COA for exact figures. The testing protocol involves microwave digestion in nitric acid, followed by analysis using a collision/reaction cell to eliminate polyatomic interferences. We also monitor chromium, nickel, and lead, as these can leach from stainless steel reactors. In our experience, a common pitfall is iron contamination from raw material storage in unlined carbon steel drums. We exclusively use HDPE-lined fiber drums or IBC totes for bulk shipments to preserve the integrity of Benzofuran-6-carbonsaeure. For R&D managers qualifying a new source, we recommend requesting a full metals scan and comparing it against your internal specifications. Our drop-in replacement for Pharmablock PBKH9AA7618C matches or exceeds the purity profile, as detailed in our technical comparison.

Filtration and Purification Strategies to Prevent Yellowing and Particulate Formation in Eye Drop Manufacturing

Yellowing and particulate formation in final ophthalmic solutions often originate from insoluble oligomers or metal complexes formed during API synthesis. When using 1-Benzofuran-6-carboxylic acid as a key intermediate, we advise a two-step purification protocol:

• Step 1: Hot filtration with activated carbon. Dissolve the crude acid in ethanol at 50°C, add 2% w/w activated carbon, stir for 30 minutes, and filter through a 0.45 µm PTFE membrane. This removes colored impurities and adsorbs residual metals.
• Step 2: Recrystallization from ethanol/water (70:30 v/v). Cool the filtrate slowly to 5°C to obtain pale yellow crystals. If the product appears brown, repeat the carbon treatment. Note: rapid cooling can trap impurities, leading to a lower melting point (observed at 155°C instead of the typical 158-162°C).

In our plant, we have encountered a non-standard behavior: at sub-zero temperatures during winter transport, the crystalline solid can develop a slight surface tackiness due to amorphous phase formation. This does not affect chemical purity but may complicate dispensing. We recommend warming the container to 20°C before opening. For large-scale manufacturing, our 6-Benzofurancarboxylic Acid is supplied in 210L drums with secure seals to prevent moisture ingress. For Japanese-speaking clients, our ドロップイン代替品 documentation provides additional handling guidance.

Drop-in Replacement Qualification: Matching Purity Profiles and Supply Chain Reliability for 1-Benzofuran-6-carboxylic Acid

Qualifying a second source for 1-Benzofuran-6-carboxylic acid requires rigorous comparison of impurity profiles, not just assay. Our product is designed as a seamless drop-in replacement for Pharmablock PBKH9AA7618C, with identical retention times in HPLC and matching residual solvent levels. In a head-to-head study, our batch showed 99.5% purity by HPLC versus 99.4% for the reference, with single unknown impurities below 0.10%. The synthesis route—starting from benzofuran via Friedel-Crafts acylation followed by oxidation—is robust and scalable, ensuring consistent quality from lab to metric ton quantities. Supply chain reliability is equally critical: we maintain safety stock in multiple warehouses and offer flexible packaging from 1 kg to bulk IBC totes. Our factory supply model eliminates distributor markups, providing cost efficiency without compromising on technical parameters. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.

Frequently Asked Questions

What impurity thresholds should I specify for ophthalmic use of 1-Benzofuran-6-carboxylic acid?

For ophthalmic APIs, we recommend total impurities ≤0.5%, with any single unknown impurity ≤0.10%. Metals should meet ICH Q3D limits for parenteral products: Cu ≤1.0 ppm, Fe ≤2.0 ppm. Please refer to the batch-specific COA for exact values.

What purification steps do you recommend before using this intermediate in eye drop synthesis?

We recommend recrystallization from ethanol/water (70:30) with activated carbon treatment to remove colored impurities and trace metals. For critical applications, a final polish filtration through 0.22 µm membrane is advised.

Is 1-Benzofuran-6-carboxylic acid compatible with standard coupling reagents like HATU or EDC in aqueous-organic systems?

Yes, it is fully compatible. The carboxylic acid group activates smoothly with HATU, EDC, or mixed anhydride methods. In aqueous-organic mixtures (e.g., THF/water), we have observed no racemization or ring-opening side reactions under standard conditions (pH 6-8, 0-25°C).

What is the use of benzofuran?

Benzofuran derivatives are used as pharmaceutical intermediates, particularly in ophthalmic drugs, antiarrhythmics, and antidepressants. The 6-carboxylic acid variant serves as a key building block for API synthesis.

How to prepare carboxylic acid from Grignard reagent?

Carboxylic acids can be prepared by reacting a Grignard reagent with carbon dioxide, followed by acidic hydrolysis. However, for benzofuran-6-carboxylic acid, industrial routes typically involve oxidation of the corresponding methyl or formyl derivative.

Sourcing and Technical Support

NINGBO INNO PHARMCHEM CO.,LTD. delivers 1-Benzofuran-6-carboxylic acid with the consistency and purity demanded by sterile ophthalmic manufacturing. Our process engineers are available to discuss your specific impurity limits, packaging needs, and qualification protocols. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.